Patients must be able to swallow tablets wholeXx_NEWLINE_xXPatients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligibleXx_NEWLINE_xXPatients must be able to swallow tabletsXx_NEWLINE_xXPatients must be able to swallow tabletsXx_NEWLINE_xXAbility to swallow abiraterone acetate tablets as a wholeXx_NEWLINE_xXPatients who are unable to swallow whole tablets are not eligibleXx_NEWLINE_xXPatients who are unable to swallow intact tablets are not eligibleXx_NEWLINE_xXPatients must be able to swallow intact tabletsXx_NEWLINE_xXPatients must be able to swallow intact tabletsXx_NEWLINE_xXPatients must be able to swallow intact tabletsXx_NEWLINE_xXPatients must be able to swallow intact tabletsXx_NEWLINE_xXAbility to swallow tabletsXx_NEWLINE_xXPatients must be able to swallow tabletsXx_NEWLINE_xXEligible patients have a body surface area >= 0.7 m^2 AND be able to swallow whole tablets at the time of study enrollmentXx_NEWLINE_xXPatients who are unable to swallow whole tablets are not eligibleXx_NEWLINE_xXAbility to swallow the investigational product tablets.Xx_NEWLINE_xXParticipants must be able to swallow ribociclib capsules or tabletsXx_NEWLINE_xXInability to swallow intact tabletsXx_NEWLINE_xXInability to swallow intact tabletsXx_NEWLINE_xXParticipant is unable to swallow or absorb oral tablets.Xx_NEWLINE_xXMust be able to swallow ribociclib and everolimus capsules/tabletsXx_NEWLINE_xXMust be able to swallow LEE011 and everolimus capsules/tabletsXx_NEWLINE_xXPatients must have the ability to swallow tabletsXx_NEWLINE_xXPatients who are unable to swallow tablets or liquid are not eligible.Xx_NEWLINE_xXThe participant is unable to swallow tablets that are whole (do not crush or chew or administer via nasogastric [NG]-tube)Xx_NEWLINE_xXGastrointestinal disorder affecting absorption or the ability to swallow tabletsXx_NEWLINE_xXPatients must be able to swallow tablets (or applesauce, if part of bioavailability \crushed\ six patient cohort)Xx_NEWLINE_xXUnable or unwilling to swallow tablets as per dosing scheduleXx_NEWLINE_xXSubjects that cannot swallow tablets.Xx_NEWLINE_xXSubject is unable to swallow or absorb oral tablets normallyXx_NEWLINE_xXUnable or unwilling to swallow tablets or capsulesXx_NEWLINE_xXAble to swallow tablets.Xx_NEWLINE_xXPatients who are unable to swallow erlotinib tablets are not eligibleXx_NEWLINE_xXPatients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowedXx_NEWLINE_xXPatients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowedXx_NEWLINE_xXParticipant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible.Xx_NEWLINE_xXPatients who are unable to swallow tablets or have a gastrointestinal disease that could hinder the absorption of enzalutamide.Xx_NEWLINE_xXAbility to swallow oral tablets without difficultyXx_NEWLINE_xXPatients must be able to swallow intact tabletsXx_NEWLINE_xXPatients who are not able to swallow intact tablets are not eligibleXx_NEWLINE_xXUnable to swallow tablets.Xx_NEWLINE_xXInability to swallow intact tabletsXx_NEWLINE_xXUnable or unwilling to swallow tablets or capsulesXx_NEWLINE_xXInability to swallow intact tabletsXx_NEWLINE_xXInability to swallow intact tabletsXx_NEWLINE_xXHas an inability to swallow tablets or capsulesXx_NEWLINE_xXUnable or unwilling to swallow tabletsXx_NEWLINE_xXAble to swallow bicalutamide and ribociclib capsules/tablets.Xx_NEWLINE_xXPatient must be capable of swallowing the ruxolitinib capsules (tablets)Xx_NEWLINE_xXBe able to swallow tablets.Xx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXAre able to swallow capsules and tablets.Xx_NEWLINE_xXPatients must be able to swallow intact tablets; patients who cannot swallow intact tablets are not eligibleXx_NEWLINE_xXAble to swallow the study drugs whole as tabletsXx_NEWLINE_xXPatients must be able to swallow whole tabletsXx_NEWLINE_xXUnable or unwilling to swallow tabletsXx_NEWLINE_xXCAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsulesXx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsulesXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsulesXx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsulesXx_NEWLINE_xXPatient has a condition that would prevent him or her from being able to swallow Toca FC tablets or absorb flucytosine.Xx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXInability to swallow tablets or capsulesXx_NEWLINE_xXSubject is unable to swallow or absorb oral tablets normallyXx_NEWLINE_xXUnable to swallow tabletsXx_NEWLINE_xXAbility to swallow and retain oral tabletsXx_NEWLINE_xXPatients who cannot swallow whole tablets (i.e. medication tablets)Xx_NEWLINE_xXUnwilling or unable to swallow tablets BIDXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXCOHORTS 1 AND 2: HEALTHY VOLUNTEERS: Ability to swallow capsules or tabletsXx_NEWLINE_xXWilling to take abiraterone acetate on an empty stomach, and should be able to swallow tablets whole, without crushing/chewing tablets; must have the ability to swallow, retain, and absorb oral medicationXx_NEWLINE_xXPart E: Are able to swallow capsules or tabletsXx_NEWLINE_xXAbility to swallow epacadostat tablets. In case Incyte at a later time point provides support to administer epacadostat tablets parenterally (via gastrostomy [G]-tube), such administration would also be acceptable as an alternative (once official documentation has been obtained from Incyte)Xx_NEWLINE_xXThe subject must be able to swallow tablets, or receive tablets crushed and/or dispensed in water via nasogastric or orogastric tube.Xx_NEWLINE_xXPatients must be able to swallow tablets and have no significant impairment in gastrointestinal absorptionXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXPatients who are not able to swallow capsules or tabletsXx_NEWLINE_xXThe subject is unable to swallow capsules or tabletsXx_NEWLINE_xXMust be able to swallow ribociclib and tamoxifen capsules/tabletsXx_NEWLINE_xXPatients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal functionXx_NEWLINE_xXPatients must be able to swallow tablets wholeXx_NEWLINE_xXUnable or unwilling to swallow tablets BIDXx_NEWLINE_xXPatients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy (G)-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowedXx_NEWLINE_xXPatients must be able to swallow capsules/tabletsXx_NEWLINE_xXPatients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewedXx_NEWLINE_xXFor subjects to be enrolled in Cohort 4: Able to swallow and retain orally administered tabletsXx_NEWLINE_xXPatients must have the ability to swallow tabletsXx_NEWLINE_xXUnable or unwilling to swallow tabletsXx_NEWLINE_xXAbility to swallow and retain oral tabletsXx_NEWLINE_xXUnable to swallow tabletsXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXAre able to swallow capsules and tablets.Xx_NEWLINE_xXAny condition causing an inability to swallow tablets.Xx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXMust be able to swallow ribociclib / placebo capsules/tabletsXx_NEWLINE_xXPatients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal functionXx_NEWLINE_xXInability to swallow tabletsXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXUnable to swallow tablets, or diagnosed malabsorption syndrome, or any other disease significantly affecting gastrointestinal functionXx_NEWLINE_xXInability to swallow tablets or capsulesXx_NEWLINE_xXAble to swallow tabletsXx_NEWLINE_xXInability to swallow tabletsXx_NEWLINE_xXPatients must be willing and able to swallow oral tabletsXx_NEWLINE_xXPatients must have the ability to swallow tabletsXx_NEWLINE_xXCapable of swallowing tabletsXx_NEWLINE_xXInability to swallow tablets or use of a feeding tubeXx_NEWLINE_xXPatients who are unable or unwilling to swallow tabletsXx_NEWLINE_xXAre able to swallow and retain oral tabletsXx_NEWLINE_xXParticipant is unable or unwilling to swallow tabletsXx_NEWLINE_xXWilling to take abiraterone acetate on an empty stomach; no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken, and should be able to swallow tablets whole, without crushing/chewing tabletsXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXAre able to swallow tabletsXx_NEWLINE_xXPatients must be able to swallow tabletsXx_NEWLINE_xXPatients with an inability to swallow tablets or capsulesXx_NEWLINE_xXThe subject is unable to swallow capsules tabletsXx_NEWLINE_xXThe participant is unable to swallow capsules or tabletsXx_NEWLINE_xXAre able to swallow capsules or tabletsXx_NEWLINE_xXPatients who are unable to swallow tabletsXx_NEWLINE_xXAbility to swallow tablets without difficulty;Xx_NEWLINE_xXPatients must be able to swallow tabletsXx_NEWLINE_xXAble to swallow tabletsXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXAbility to swallow intact palbociclib capsules and bicalutamide tabletsXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXUnable to swallow tablets, or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function.Xx_NEWLINE_xXSubject is unable to swallow capsules or tabletsXx_NEWLINE_xXPatients must be able to swallow whole tablets (for MK-2206); nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewedXx_NEWLINE_xXPatients who are not able to swallow capsules or tabletsXx_NEWLINE_xXAbility to swallow tablets.Xx_NEWLINE_xXPatients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewedXx_NEWLINE_xXUnable or unwilling to swallow BBI608, BBI503, or sorafenib capsules or tabletsXx_NEWLINE_xXPatients must be able to swallow tablets whole, without crushingXx_NEWLINE_xXPatients must be able to swallow whole tablets; tablets must not be crushed or chewedXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXThe subject is unable to swallow tabletsXx_NEWLINE_xXPatients must be able to swallow whole tablets and capsulesXx_NEWLINE_xXInability to swallow tablets for everolimus armXx_NEWLINE_xXPatient must be able to swallow whole tabletsXx_NEWLINE_xXPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulationXx_NEWLINE_xXPatients must be able to swallow tabletsXx_NEWLINE_xXPatients must be able to swallow tabletsXx_NEWLINE_xXMust be able to swallow tablets and capsulesXx_NEWLINE_xXInability to swallow tabletsXx_NEWLINE_xXInability to swallow tabletsXx_NEWLINE_xXAbility to swallow oral tabletsXx_NEWLINE_xXAbility to swallow and tolerate oral tabletsXx_NEWLINE_xXGENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assignedXx_NEWLINE_xXSubjects must be able to swallow capsules/tabletsXx_NEWLINE_xXPatients must be able to swallow whole tablets or capsules; nasogastric or g-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowedXx_NEWLINE_xX